

Basingstoke, Southampton and Winchester

District Prescribing Committee (DPC)

Recommendations of the meeting of 12th August 2014

Supported or limited support e.g. Specialist recommendation

- **Sildenafil as an option in Raynaud's phenomenon-** The DPC supported this in principle, on the basis that although unlicensed for this indication, it may prevent admissions for injectable last line alternatives. In addition the DPC asked for an algorithm to show its planned place in the treatment pathway, and a short shared care guideline to support GP continuation.
- **Brimonidine gel (Mirvaso®), new topical agent for rosacea-** This was supported as an option for use in patients who have failed to respond to, or are intolerant of, other options, or have psychological distress due to persistent redness. Cautious use is advised until more data are available around long-term safety and potential loss of effect in longer-term use.
- **Domperidone off-license use for the stimulation of lactation-** Niche use short term for up to 10 days continues to be supported in mothers with no known cardiac problems.
- **Minoxidil tablets supported for 'amber' combination use in severe hypertension following specialist recommendation-** removed from the local 'red' list and agreed as 'amber' for practical purposes henceforth.

Not supported currently

- **Lurasidone (Lutada®), new antipsychotic for schizophrenia-** Routine use was not supported at this time, due to a lack of evidence that lurasidone is superior to less expensive alternatives, and a lack of long-term safety and efficacy data .

Other Information/ Reminders

- **Emergency Hormonal Contraception-** Following recent clarification from the EMEA and MHRA, the DPC noted that in contrast to previous discussions at the April meeting, there is no conclusive evidence to support the use of ulipristal (EllaOne®) in preference to levonelle first line in "larger ladies". **Levonelle remains a first line oral option for use up to 72 hours post coitus in all women, with IUD fitting or ulipristal an option up to 5 days.**
- **PDE5 inhibitors for erectile dysfunction following prostatectomy-**The use of generic sildenafil first line, prescribed as on-demand treatment, continues to be supported as an option. Regular use of tadalafil, or other agents such as avanafil, was not supported, due to a lack of clinical evidence and cost-effectiveness when compared to on-demand treatment.
- **Updated Osteoporosis and denosumab shared care guidelines-** updated to include the latest safety guidance and the option of initiation of denosumab in primary care.
- **Updated methotrexate shared care guidelines-** updated to include the availability of a new range of **Metoject® pre-filled single use pen devices** (50mg/ml) to support self-administration for various indications.
- **Type 2 Diabetes Stepped Approach Guidance** - Updated and supported for local use. Final guidance will be available soon via the West Hampshire CCG website (no password required)
http://www.westhampshireccg.nhs.uk/documents/cat_view/84-medicines/92-guidance-

Summarised on behalf of the District Prescribing Committee

Julia Bowey (Southampton City CCG) 15.08.14